Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680549 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| Ethylene Glycol SCHEMBL3625093 | 0.97 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| Sulfuric Acid SCHEMBL7496979 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| Sulfuric Acid SCHEMBL7504984 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL26945939 | 0.92 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL6064367 | 0.92 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL19293541 | 0.92 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL6658547 | 0.91 | PTGS1 (0.57) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL24359832 | 0.90 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL14842415 | 0.90 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12427138-B2 | Treatment of Meniere's disease | SOUND PHARMACEUTICALS INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4461360-A2 | TREATMENT OF MENIERE'S DISEASE | Sound Pharmaceuticals Incorporated (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-3458045-B1 | EBSELEN FOR USE IN THE TREATMENT OF MENIERE'S DISEASE | SOUND PHARMACEUTICALS INCORPORATED (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240050409-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2024-02-15 | — | — | US | disclosed |
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | disclosed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | disclosed |
| US-20210379017-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2021-12-09 | — | — | US | disclosed |
| WO-2017201318-A1 | TREATMENT OF MENIERE'S DISEASE | SOUND PHARMACEUTICALS INCORPORATED (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2017-08-31 | — | — | US | disclosed |
| US-4879370-A | ALKYL ESTER TO INCREASE CELLULAR LEVELS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4784685-A | MONOALKYL ESTERS OF GLUTATHIONE TO YIELD GLUTATHIONE | CORNELL RESEARCH FOUNDATION, INC. (US) | 1988-11-15 | — | — | US | disclosed |
| US-4710489-A | ADMINISTERING PURE ALKYL MONOESTERS OF GLUTATHIONE; IN VIVO HYDROLYSIS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4709013-A | ESTERIFICATION, SALT FORMATION | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379017-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 242/4885GSTK1 15/4885GLO1 184/4885 |
| US-12427138-B2 | Treatment of Meniere's disease | GPX1, GSR, GPX4 | PTGS1 77/4885GSTK1 58/4885GLO1 390/4885 |
| US-20240050409-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 242/4885GSTK1 15/4885GLO1 184/4885 |
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 235/4885GSTK1 14/4885GLO1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.